Daily consumption of the probiotic strain Lactobacillus salivarius UCC118 helped relieve severity of gastrointestinal (GI) symptoms associated with small intestinal bacterial overgrowth (SIBO), according to a pilot quality improvement study.
The study participants (n=29) were recruited from patients who presented to the Cleveland Clinic Center for Gut Rehabilitation and Transplantation outpatient clinic (Cleveland, OH). Participants consumed the probiotic strain Lactobacillus salivarius UCC118 in an oral supplement (108 CFU/capsule daily) for 90 days in addition to standard therapy. GI symptoms consistent with SIBO, such as diarrhea, bloating, foul stool, flatulence, and stool characteristics, were assessed at baseline, 30, 60, and 90 days. The data demonstrated that daily consumption of the probiotic strain Lactobacillus salivarius UCC118 was effective in relieving the severity of several GI symptoms and negating or delaying the need for antibiotic therapy.
These results were presented as a scientific poster1 by Gail Cresci, PhD, RD (Cleveland Clinic) at Clinical Nutrition Week 2016 hosted by the American Society for Parenteral and Enteral Nutrition (ASPEN) in Austin, TX.
Citation
- Cresci G, Izzo K, Furman A, Melnick L, Shantnawei A. Effects of Lactobacillus salivarius UCC118 in reducing symptoms of small intestinal bacterial overgrowth [abstract].
